Drug Patents owned by Actelion
1. List of Opsumit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7094781 | ACTELION | Sulfamides and their use as endothelin receptor antagonists |
Dec, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10946015 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Sep, 2026
(3 years from now) | |
| US9265762 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
May, 2027
(4 years from now) | |
| US8367685 | ACTELION | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
Oct, 2028
(5 years from now) | |
| US8268847 | ACTELION | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor |
Apr, 2029
(6 years from now) | |
Drugs and Companies using MACITENTAN ingredient
Market Authorisation Date: 18 October, 2013
Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherin the polysorbate represents 0.1 to 1% of the weight of said pharmaceutical composition; Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 3% of the weight of said pharmaceutical composition; Method of treating pulmonary hypertension comprising administering macitentan in combination with a compound having phosphodiesterase-5 inhibitory properties
Dosage: TABLET;ORAL
OPSUMIT family patents
18
United States
8
European Union
4
Japan
4
IB
4
Norway
3
Korea, Republic of
3
Brazil
3
Australia
3
Malaysia
3
Spain
3
Israel
3
South Africa
3
Portugal
3
China
3
Canada
3
New Zealand
3
Denmark
2
Hong Kong
2
Poland
2
Cyprus
2
Mexico
2
Slovenia
2
Argentina
2
Russia
2
Croatia
2
Taiwan, Province of China
1
Austria
1
Morocco
1
Chile
1
Luxembourg
1
Netherlands
1
Germany
1
Hungary
1
Belgium
2. List of Tracleer drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8309126 | ACTELION | Dispersible bosentan tablet |
May, 2026
(3 years from now) | |
| US7959945 | ACTELION | Dispersible bosentan tablet |
Dec, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 5, 2024 |
Drugs and Companies using BOSENTAN ingredient
Market Authorisation Date: 05 September, 2017
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
TRACLEER family patents
4
United States
2
Korea, Republic of
2
Russia
2
European Union
1
Austria
1
Hong Kong
1
Brazil
1
Australia
1
Poland
1
Spain
1
Germany
1
Israel
1
Cyprus
1
Mexico
1
Japan
1
Slovenia
1
IB
1
South Africa
1
Portugal
1
China
1
Norway
1
New Zealand
1
Canada
1
Denmark
3. List of Uptravi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7205302 | ACTELION | Heterocyclic compound derivatives and medicines |
Oct, 2026
(3 years from now) | |
| US8791122 | ACTELION | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same |
Aug, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173881 | ACTELION | Therapeutic compositions containing macitentan |
Aug, 2029
(6 years from now) | |
| US9284280 | ACTELION | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Jun, 2030
(7 years from now) | |
| US10828298 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide |
Dec, 2036
(13 years from now) | |
| US10821108 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Dec, 2036
(13 years from now) | |
Drugs and Companies using SELEXIPAG ingredient
Market Authorisation Date: 29 July, 2021
Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan; Method of treating pulmonary arterial hypertension comprising administering a crystalline form of selexipag; Method of treating pulmonary arterial hypertension comprising administering a tablet containing selexipag; Method of treating pulmonary arterial hypertension comprising administering a solid preparation containing selexipag; Method of treating pulmonary arterial hypertension comprising administering a pharmaceutical composition comprising selexipag
Dosage: POWDER;INTRAVENOUS
UPTRAVI family patents
14
Japan
13
United States
7
European Union
5
Korea, Republic of
5
Brazil
5
Lithuania
5
Spain
5
Mexico
5
Hungary
5
Portugal
5
China
5
Denmark
4
Poland
4
Slovenia
4
Russia
4
Croatia
4
Canada
4
Taiwan, Province of China
3
Australia
3
Israel
3
Cyprus
3
Argentina
3
South Africa
3
Singapore
3
Philippines
3
Norway
2
Morocco
2
Hong Kong
2
Chile
2
Malaysia
2
Ukraine
2
IB
2
Colombia
2
New Zealand
1
Luxembourg
1
Netherlands
1
Germany
1
Belgium
1
Peru
1
Ecuador
4. List of Veletri drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8598227 | ACTELION | Epoprostenol formulation and method of making thereof |
Feb, 2027
(3 years from now) | |
| US8318802 | ACTELION | Epoprostenol formulation and method of making thereof |
Mar, 2027
(4 years from now) | |
Drugs and Companies using EPOPROSTENOL SODIUM ingredient
Market Authorisation Date: 27 June, 2008
Treatment: NA
Dosage: INJECTABLE;INJECTION
VELETRI family patents
10
United States
2
Canada
1
Slovenia
1
Hungary
1
Korea, Republic of
1
Brazil
1
Spain
1
Portugal
1
Poland
1
Russia
1
Cyprus
1
Denmark
1
China
1
Japan
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic